Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The role of hospital pharmacists in supporting the appropriate and safe use of CGT/ATMPs: a scoping review of current insights.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963 (Electronic) Linking ISSN: 14726963 NLM ISO Abbreviation: BMC Health Serv Res Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Cell- and Tissue-Based Therapy*/adverse effects ; Cell- and Tissue-Based Therapy*/methods ; Genetic Therapy*/adverse effects ; Genetic Therapy*/methods ; Pharmacists*/organization & administration ; Pharmacy Service, Hospital*/organization & administration ; Professional Role*; Humans
    • Abstract:
      Background: The role of hospital pharmacists in managing cell and gene therapy (CGT) and advanced therapy medicinal products (ATMPs) is gradually being recognized but the evidence about impact of their role has not been systematically reported.
      Objective: This study was aimed to summarize the professional services provided by hospital pharmacists on managing CGT/ATMPs and the evidence about the effects on patient care, as well as to identify the perceptions about pharmacists assuming a role that supports the appropriate and safe use of CGT/ATMPs.
      Methods: Literature from 4 electronic databases (PubMed, ScienceDirect, Web of Science, Scopus) were searched following PRISMA checklist to yield publications on the interventions provided by hospital pharmacists in the management of CGT/ATMPs dated since 1 January 2013 till 30 April 2023.
      Results: Thirty-four publications were included in this review. Eight studies involving hospital pharmacists participating in interventions for 1,012 hematopoietic stem cell transplant (HSCT) patients from 8 hospitals in 5 countries were identified. Common pharmacist-led interventions centered on medicine administration, prescribing, and monitoring of medicines use, resulting in significant improvement in patient adherence, satisfaction and knowledge. Of 26 studies, the perspectives assuming their roles in CGT/ATMPs management were categorized when patients receiving ATMPs (n = 2), HSCT and cellular-based therapy (n = 12), gene therapy (n = 6), and the chimeric antigen receptor (CAR) T-cell therapy (n = 6), mainly covering procurement, influences on prescribing, preparation and delivery, administration, monitoring of medicines use, human resources, training and development. The anticipated impact was primarily intended to promote pharmacy practice, multidisciplinary collaboration and improve patient clinical outcomes.
      Conclusion: Leveraging the role of hospital pharmacists in multidisciplinary healthcare teams to develop a coordinated approach that supports pharmacy practice will better meet the management of CGT/ATMPs. For hospital pharmacists to step up their role in the multidisciplinary healthcare team, advancing their skillset in terms of clinical practice standards and medication management is essential.
      Competing Interests: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
      (© 2024. The Author(s).)
    • References:
      Bone Marrow Transplant. 2020 Jan;55(1):62-69. (PMID: 31101890)
      Transfus Med Hemother. 2022 May 25;49(3):127-128. (PMID: 35813603)
      Therapie. 2022 Mar-Apr;77(2):185-190. (PMID: 34895758)
      Am J Health Syst Pharm. 2021 May 24;78(11):953-961. (PMID: 33677501)
      Am J Pharm Educ. 2022 Aug;86(6):8773. (PMID: 34697019)
      Biol Blood Marrow Transplant. 2019 Jan;25(1):26-33. (PMID: 30266675)
      J Pharm Pract. 2021 Jun;34(3):472-479. (PMID: 32583733)
      Front Oncol. 2021 Mar 11;11:636068. (PMID: 33777790)
      Front Cell Dev Biol. 2020 Dec 17;8:547653. (PMID: 33392179)
      Bone Marrow Transplant. 2023 Jul;58(7):829-831. (PMID: 37029183)
      J Pharm Pract. 2020 Dec;33(6):846-855. (PMID: 31248331)
      Transplant Cell Ther. 2022 Jun;28(6):334.e1-334.e9. (PMID: 35189400)
      Am J Health Syst Pharm. 2023 Jul 7;80(14):944-947. (PMID: 37010889)
      J Oncol Pharm Pract. 2019 Dec;25(8):1945-1967. (PMID: 31288634)
      Front Pharmacol. 2019 Aug 30;10:921. (PMID: 31543814)
      Clin Ther. 1993 Nov-Dec;15(6):1121-32; discussion 1120. (PMID: 8111809)
      J Pharm Pract. 2023 Dec;36(6):1532-1539. (PMID: 35583499)
      Cytotherapy. 2021 Mar;23(3):261-274. (PMID: 33483292)
      Res Social Adm Pharm. 2021 Sep;17(9):1532-1545. (PMID: 33423904)
      Am J Health Syst Pharm. 2019 May 17;76(11):795-802. (PMID: 31361814)
      J Pharm Sci. 2021 May;110(5):1877-1884. (PMID: 32918916)
      J Am Pharm Assoc (2003). 2021 May-Jun;61(3):e78-e82. (PMID: 33342748)
      Am J Health Syst Pharm. 2018 Jul 15;75(14):1039-1047. (PMID: 29789318)
      Biol Blood Marrow Transplant. 2018 May;24(5):914-922. (PMID: 29292057)
      J Oncol Pharm Pract. 2019 Apr;25(3):558-566. (PMID: 29207938)
      Support Care Cancer. 2013 Dec;21(12):3491-5. (PMID: 23963769)
      Biol Blood Marrow Transplant. 2013 Apr;19(4):505-6. (PMID: 23416093)
      J Oncol Pharm Pract. 2019 Jul;25(5):1217-1225. (PMID: 30890066)
      J Oncol Pharm Pract. 2023 Mar;29(2):375-385. (PMID: 35037789)
      Innov Pharm. 2023 Oct 10;14(2):. (PMID: 38025167)
      Clin Nucl Med. 2016 Feb;41(2):134-6. (PMID: 26545019)
      Ann Intern Med. 2018 Oct 2;169(7):467-473. (PMID: 30178033)
      J Oncol Pract. 2016 Feb;12(2):147-8, e118-26. (PMID: 26787757)
      Eur J Hosp Pharm. 2024 Aug 22;31(5):390-402. (PMID: 38821721)
      J Oncol Pharm Pract. 2021 Mar 8;:10781552211000115. (PMID: 33683151)
      Can J Hosp Pharm. 2013 Mar;66(2):110-7. (PMID: 23616675)
      Biotechnol Adv. 2020 May - Jun;40:107502. (PMID: 31887345)
      J Oncol Pharm Pract. 2020 Oct;26(7):1725-1731. (PMID: 32819199)
      Farm Hosp. 2020 Jan 01;44(1):26-31. (PMID: 31901059)
      Biol Blood Marrow Transplant. 2020 Jun;26(6):1043-1049. (PMID: 32305359)
      Drug Discov Today. 2023 May;28(5):103549. (PMID: 36963609)
      J Oncol Pharm Pract. 2021 Dec;27(8):1907-1913. (PMID: 33250016)
      Cancer Cell Int. 2022 Nov 24;22(1):365. (PMID: 36419058)
      Res Social Adm Pharm. 2013 May-Jun;9(3):311-29. (PMID: 22835704)
      J Clin Pharm Ther. 2021 Dec;46(6):1665-1679. (PMID: 34397108)
      Per Med. 2021 Sep;18(5):509-522. (PMID: 34402307)
      Biol Blood Marrow Transplant. 2013 Apr;19(4):509-18. (PMID: 23419976)
      J Oncol Pharm Pract. 2019 Apr;25(3):607-612. (PMID: 29451420)
      J Clin Med Res. 2020 Dec;12(12):780-786. (PMID: 33447311)
      Am J Manag Care. 2017 Oct;23(12 Spec No.):SP480-SP481. (PMID: 29087666)
      Pharmacy (Basel). 2020 Jan 02;8(1):. (PMID: 31906486)
      Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jul;54(7):843-8. (PMID: 21698538)
      Expert Opin Biol Ther. 2018 Aug;18(8):837-840. (PMID: 29962243)
      Clin Pharmacol Ther. 2023 Sep;114(3):569-577. (PMID: 37309988)
      Yale J Biol Med. 2017 Mar 29;90(1):125-133. (PMID: 28356900)
      Am J Pharm Educ. 2014 Feb 12;78(1):22. (PMID: 24558290)
    • Grant Information:
      MYRG2022-00229-ICMS Universidade de Macau
    • Contributed Indexing:
      Keywords: Advanced therapy medicinal products; Cell and gene therapy; Hospital pharmacy; Pharmaceutical care; Pharmacy practice; Regeneration medicine
    • Publication Date:
      Date Created: 20250109 Date Completed: 20250110 Latest Revision: 20250130
    • Publication Date:
      20250130
    • Accession Number:
      PMC11721208
    • Accession Number:
      10.1186/s12913-024-12026-4
    • Accession Number:
      39789612